Abbott Laboratories $ABT Shares Bought by New Mexico Educational Retirement Board

New Mexico Educational Retirement Board lifted its stake in shares of Abbott Laboratories (NYSE:ABT) by 7.7% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 86,402 shares of the healthcare product maker’s stock after acquiring an additional 6,200 shares during the period. New Mexico Educational Retirement Board’s holdings in Abbott Laboratories were worth $7,840,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the company. Mufg Securities Americas Inc. lifted its holdings in Abbott Laboratories by 9.1% in the 2nd quarter. Mufg Securities Americas Inc. now owns 52,461 shares of the healthcare product maker’s stock valued at $4,760,000 after purchasing an additional 4,356 shares in the last quarter. Investors Asset Management of Georgia Inc. GA ADV grew its holdings in shares of Abbott Laboratories by 15.6% during the second quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 5,412 shares of the healthcare product maker’s stock worth $491,000 after buying an additional 730 shares in the last quarter. Nissay Asset Management Corp Japan raised its position in shares of Abbott Laboratories by 2.1% in the second quarter. Nissay Asset Management Corp Japan now owns 231,778 shares of the healthcare product maker’s stock valued at $21,032,000 after buying an additional 4,797 shares during the last quarter. Chapin Davis Inc. raised its position in shares of Abbott Laboratories by 11.4% in the second quarter. Chapin Davis Inc. now owns 5,466 shares of the healthcare product maker’s stock valued at $496,000 after buying an additional 558 shares during the last quarter. Finally, Tandem Capital Management Corp ADV lifted its stake in shares of Abbott Laboratories by 5.6% during the second quarter. Tandem Capital Management Corp ADV now owns 30,998 shares of the healthcare product maker’s stock valued at $2,813,000 after buying an additional 1,655 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on the stock. Wells Fargo & Company lifted their target price on shares of Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. JPMorgan Chase & Co. increased their price target on Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. TD Cowen lifted their price objective on Abbott Laboratories from $115.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, August 25th. Weiss Ratings upgraded Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 6th. Finally, Bank of America lowered their price target on Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $119.50.

Abbott Laboratories Price Performance

Shares of Abbott Laboratories stock opened at $108.29 on Friday. The business’s fifty day moving average price is $104.43 and its 200 day moving average price is $100.12. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $187.38 billion, a P/E ratio of 35.05, a PEG ratio of 2.02 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. The company had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm’s revenue was up 13.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, research analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were issued a $0.63 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 81.55%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.